Aimmune Therapeutics Inc. (AIMT)

18.34
NASDAQ : Health Technology
Prev Close 18.09
Day Low/High 17.86 / 18.51
52 Wk Low/High 16.95 / 36.12
Avg Volume 507.10K
Exchange NASDAQ
Shares Outstanding 62.49M
Market Cap 1.13B
EPS -3.70
P/E Ratio N/A
Div & Yield N.A. (N.A)
Aimmune Therapeutics To Present At The Piper Jaffray 27th Annual Healthcare Investor Conference

Aimmune Therapeutics To Present At The Piper Jaffray 27th Annual Healthcare Investor Conference

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced that it will present at the Piper Jaffray 27th Annual Healthcare Investor...

Aimmune Therapeutics Reports Positive Findings For ARC002 Follow-On Phase 2 Study Of AR101 For Treatment Of Peanut Allergy

Aimmune Therapeutics Reports Positive Findings For ARC002 Follow-On Phase 2 Study Of AR101 For Treatment Of Peanut Allergy

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced positive findings for its ARC002 clinical trial, a follow-on Phase 2 study of...

Aimmune Therapeutics Announces Financial Results For The Third Quarter 2015

Aimmune Therapeutics Announces Financial Results For The Third Quarter 2015

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced financial results for the third quarter and nine months ended September 30,...

Aimmune Therapeutics To Present At The 2015 Credit Suisse Healthcare Conference

Aimmune Therapeutics To Present At The 2015 Credit Suisse Healthcare Conference

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced that it will present at the 2015 Credit Suisse Healthcare Investor Conference.

Aimmune Therapeutics is Now Oversold (AIMT)

Aimmune Therapeutics is Now Oversold (AIMT)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Aimmune Therapeutics Announces COO Transition

Aimmune Therapeutics Announces COO Transition

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced that Aimmune's Chief Operating Officer, Howard Raff, Ph.

Aimmune Therapeutics Receives EMA Decision Agreeing With PIP For AR101 For The Treatment Of Peanut Allergy

Aimmune Therapeutics Receives EMA Decision Agreeing With PIP For AR101 For The Treatment Of Peanut Allergy

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced that it has received the European Medicines Agency (EMA) decision endorsing the...

5 Stocks Ready for Breakouts

5 Stocks Ready for Breakouts

These stocks look ready to break out and trade higher from current levels.

Aimmune Therapeutics To Present At The Bank Of America Merrill Lynch Global Healthcare Conference

Aimmune Therapeutics To Present At The Bank Of America Merrill Lynch Global Healthcare Conference

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced that it will present at the Bank of America Merrill Lynch Global Healthcare...

Aimmune Therapeutics Reports Second Quarter 2015 Financial Results

Aimmune Therapeutics Reports Second Quarter 2015 Financial Results

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced financial results for the second quarter and six months ending June 30, 2015.

Aimmune Therapeutics Announces Closing Of Initial Public Offering And Full Exercise Of Underwriters' Option To Purchase Additional Shares

Aimmune Therapeutics Announces Closing Of Initial Public Offering And Full Exercise Of Underwriters' Option To Purchase Additional Shares

Aimmune Therapeutics, Inc., today announced the closing of its initial public offering of 11,499,999 shares of its common stock at a public offering price of $16.